Trust is a cornerstone of meaningful relationships. When dealing with businesses and brands, it's often the deciding factor that separates companies we rely on from the ones we don't. It's about ...

BofA raised the firm’s price target on Yum! Brands (YUM) to $153 from $143 and keeps a Neutral rating on the shares. The Q4 same-store sales growth beat was “modest,” but the market was ...

Barclays analyst Jeffrey Bernstein raised the firm’s price target on Yum! Brands (YUM) to $165 from $162 and keeps an Overweight rating on the shares. The company’s Q4 results beat modestly ...

In the wake of this epidemic, drug developers have been searching tirelessly for non-addictive medicines that can combat pain without triggering the brain ... overcome issues surrounding efficacy and ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about prostate cancer awareness and the FDA’s approval of a new pain medication. He also explains a study that ...

It was a crisp January morning when two drug cartel divers, dressed in full black wetsuits and hoods, plunged into the black water of the Hunter River and motored quietly toward a freighter in the ...

(CNN) — The US Food and Drug Administration ... It will be sold under the brand name Journavx. “A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate ...

US Federal officials have approved a new pain pill by Vertex Pharmaceuticals called Journavx, aimed at reducing addiction and overdose risks associated with opioids. The drug, which works by ...

"This would allow us to target treatments toward people with acute pain who are likely to transition to chronic pain," said Schabrun. "If these brain biomarkers can predict that occurrence in ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. The new development is ...